{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:18:17Z","timestamp":1791908297804,"version":"4.3.4"},"reference-count":19,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2015,6,29]],"date-time":"2015-06-29T00:00:00Z","timestamp":1435536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Alemtuzumab, a humanized monoclonal antibody targeting the surface molecule CD52, leads to a rapid depletion of immune cells in the innate and adaptive immune system. In phase 2 and 3 trials in multiple sclerosis (MS), infections have been reported more frequently in alemtuzumab than in interferon beta treated patients. Here we report two patients treated with alemtuzumab for MS developing Listeria meningitis few days after the first infusion cycle. Both patients recovered completely after prompt diagnosis and adequate treatment. Physicians and patients should be aware of this serious, but treatable complication.<\/jats:p>","DOI":"10.3390\/ijms160714669","type":"journal-article","created":{"date-parts":[[2015,6,29]],"date-time":"2015-06-29T10:05:22Z","timestamp":1435572322000},"page":"14669-14676","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Listeria Meningitis Complicating Alemtuzumab Treatment in Multiple Sclerosis\u2014Report of Two Cases"],"prefix":"10.3390","volume":"16","author":[{"given":"Daniela","family":"Rau","sequence":"first","affiliation":[{"name":"Department of Neurology, University of Ulm, Ulm 89081, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lang","sequence":"additional","affiliation":[{"name":"Neuropoint Patient Academy, Neurological Practice Center, Ulm 89073, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Harth","sequence":"additional","affiliation":[{"name":"Department of Neurology, Military Hospital, Ulm 89081, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Naumann","sequence":"additional","affiliation":[{"name":"Department of Neurology, Klinikum Augsburg, Augsburg 86156, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Neurology, Military Hospital, Ulm 89081, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1647-6201","authenticated-orcid":false,"given":"Hayrettin","family":"Tumani","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Ulm, Ulm 89081, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonios","family":"Bayas","sequence":"additional","affiliation":[{"name":"Department of Neurology, Klinikum Augsburg, Augsburg 86156, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1756285614563522","article-title":"Alemtuzumab in the treatment of multiple sclerosis: Key clinical trial results and considerations for use","volume":"8","author":"Havrdova","year":"2015","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"CAMMS223 Trial Investigators, Coles, A.J., Compston, D.A., Selmaj, K.W., Lake, S.L., Moran, S., Margolin, D.H., Norris, K., and Tandon, P.K. (2008). Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med., 359, 1786\u20131801.","DOI":"10.1056\/NEJMoa0802670"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta-1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13311-012-0159-0","article-title":"Alemtuzumab therapy for multiple sclerosis","volume":"10","author":"Coles","year":"2013","journal-title":"Neurotherapeutics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2010.29.7978","article-title":"Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: Final analysis of CALGB 10101","volume":"28","author":"Lin","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_7","unstructured":"Wray, S., and On behalf of the CAMMS223 Study Group (2009, January 9\u201312). Descriptive analysis of infectious adverse events in alemtuzumab-treated multiple sclerosis patients. Proceedings of the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, D\u00fcsseldorf, Germany."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4161\/viru.19586","article-title":"Targeting of the central nervous system by Listeria monocytogenes","volume":"3","author":"Disson","year":"2012","journal-title":"Virulence"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3201\/eid0803.010195","article-title":"Listeria monocytogenes infection in Israel and review of cases worldwide","volume":"8","author":"Levin","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1086\/508462","article-title":"Community-acquired Listeria monocytogenes meningitis in adults","volume":"43","author":"Brouwer","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s11908-008-0049-0","article-title":"Central nervous system infection with Listeria monocytogenes","volume":"10","author":"Clauss","year":"2008","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1574-695X.2008.00404.x","article-title":"Listeria monocytogenes: Epidemiology, human disease, and mechanisms of brain invasion","volume":"53","author":"Drevets","year":"2008","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.smim.2012.04.009","article-title":"Age-related changes in CD8 T cell homeostasis and immunity to infection","volume":"24","author":"Li","year":"2012","journal-title":"Semin. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1128\/CMR.14.3.584-640.2001","article-title":"Listeria pathogenesis and molecular virulence determinants","volume":"14","author":"Kuhn","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.micinf.2007.05.008","article-title":"Innate and adaptive immune responses to Listeria monocytogenes: A short overview","volume":"9","author":"Zenewicz","year":"2007","journal-title":"Microbes Infect. Inst. Pasteur"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1242\/dmm.000836","article-title":"Foci of Listeria monocytogenes persist in the bone marrow","volume":"2","author":"Hardy","year":"2009","journal-title":"Dis. Models Mech."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0378-1135(97)00132-6","article-title":"Prolonged persistence of Listeria monocytogenes after intragastric infection in corticosteroid-treated mice","volume":"58","author":"Prats","year":"1997","journal-title":"Vet. Microbiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1097\/01.tp.0000260433.86776.ec","article-title":"Alemtuzumab depletes dendritic cells more effectively in blood than in skin: A pilot study in patients with chronic lymphocytic leukemia","volume":"83","author":"Eger","year":"2007","journal-title":"Transplantation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1078\/1438-4221-00266","article-title":"The role of human dendritic cells in meningococcal and listerial meningitis","volume":"293","author":"Kurzai","year":"2003","journal-title":"Int. J. Med. Microbiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/7\/14669\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:48:30Z","timestamp":1760215710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/7\/14669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,29]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,7]]}},"alternative-id":["ijms160714669"],"URL":"https:\/\/doi.org\/10.3390\/ijms160714669","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,29]]}}}